Abstract

The human microbiome is a dynamic ecosystem essential for host physiology, metabolism, and immunity. 
Advances in microbiome engineering have opened new opportunities to prevent and treat disease by modulating 
microbial communities. Two principal approaches are synbiotics and fecal microbiota transplantation (FMT). 
Synbiotics, which combine probiotics and prebiotics, promote the growth and activity of beneficial 
microorganisms, thereby supporting intestinal barrier integrity, immune regulation, and metabolic balance. FMT, 
a practice with roots in traditional Chinese medicine and now a validated therapy for recurrent Clostridium difficile 
infection, aims to restore microbiome diversity and function through transplantation of donor stool. Beyond C. 
difficile, both strategies show promise in managing metabolic disorders, autoimmune diseases, and even 
neurological conditions, though long-term safety and mechanisms remain incompletely understood. Challenges 
include interindividual variability, limited mechanistic insights, and regulatory and ethical barriers, particularly 
around donor screening, informed consent, and commercialization of microbiome-based therapies. Innovations 
such as targeted synbiotic formulations and metabiotic approaches offer potential for precision interventions. 
Future research integrating systems biology, clinical trials, and regulatory frameworks will be crucial to harness 
microbiome engineering for personalized medicine and broader public health. Overall, synbiotics and FMT 
represent transformative tools at the interface of microbiology, immunology, and clinical practice, with potential 
to redefine therapeutic strategies for diverse human diseases.